| scholarly article | Q13442814 |
| P50 | author | Frank G. Schaap | Q42394202 |
| Tania Roskams | Q89298557 | ||
| P2093 | author name string | Peter L M Jansen | |
| Dirk J Gouma | |||
| Mina Komuta | |||
| Klaske A C Booij | |||
| Serge J L B Zweers | |||
| P2860 | cites work | Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain | Q22001492 |
| FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4 | Q22010687 | ||
| Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis | Q24305561 | ||
| Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 | ||
| Liver-specific activities of FGF19 require Klotho beta | Q24319088 | ||
| Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression | Q24336351 | ||
| Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine | Q28242281 | ||
| Actions and mode of actions of FGF19 subfamily members | Q28249481 | ||
| The Klotho gene family and the endocrine fibroblast growth factors | Q28288742 | ||
| High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis | Q28308011 | ||
| FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways | Q28741802 | ||
| Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis | Q29619610 | ||
| Relevant use of Klotho in FGF19 subfamily signaling system in vivo | Q33667883 | ||
| The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling | Q33784827 | ||
| The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. | Q34094150 | ||
| Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. | Q34197301 | ||
| Regulation of airway mucin gene expression | Q36216587 | ||
| The FGF family: biology, pathophysiology and therapy | Q36933339 | ||
| Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice | Q37303131 | ||
| FGFs and metabolism | Q37580556 | ||
| Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease | Q37781747 | ||
| Luminal leptin activates mucin-secreting goblet cells in the large bowel | Q38316186 | ||
| Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis | Q39881165 | ||
| Identification of a hormonal basis for gallbladder filling. | Q47600731 | ||
| Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptin-cholecystokinin feedback loop | Q47800070 | ||
| Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. | Q51485180 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 575-583 | |
| P577 | publication date | 2011-12-19 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract | |
| P478 | volume | 55 |
| Q40858310 | A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism |
| Q37504830 | Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure |
| Q36136449 | An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. |
| Q47424316 | Association between dietary intake and postlaparoscopic cholecystectomic symptoms in patients with gallbladder disease |
| Q59813695 | Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study |
| Q33459719 | Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment |
| Q38132058 | Bile acid receptors as targets for drug development. |
| Q57128781 | Bile acid receptors link nutrient sensing to metabolic regulation |
| Q28244875 | Bile acid signaling in metabolic disease and drug therapy |
| Q38033967 | Bile acid transporters and regulatory nuclear receptors in the liver and beyond |
| Q33881922 | Bile formation and secretion |
| Q38201380 | Bile proteome in health and disease. |
| Q50167978 | Cholecystectomy Causes Ultrasound Evidence of Increased Hepatic Steatosis |
| Q43637362 | Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? |
| Q50151468 | Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. |
| Q35221820 | Cholecystectomy does not significantly increase the risk of fatty liver disease |
| Q90452085 | Cholecystectomy does not worsen progression or outcomes in non-alcoholic fatty liver disease |
| Q30410638 | Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population |
| Q93060092 | Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey |
| Q47235472 | Cholecystectomy: a way forward and back to metabolic syndrome? |
| Q92326834 | Cholestatic liver diseases: An era of emerging therapies |
| Q36389501 | Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis |
| Q45222692 | Cynomolgus monkey gallbladder bile contains high concentrations of fibroblast growth factor 19. |
| Q52885250 | Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. |
| Q24629260 | Endocrine fibroblast growth factors 15/19 and 21: from feast to famine |
| Q37337378 | Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice |
| Q34323617 | Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene. |
| Q37666302 | FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway |
| Q47140461 | Fibroblast Growth Factor 19 Activates the Unfolded Protein Response and Mitogen-Activated Protein Kinase Phosphorylation in H-69 Cholangiocyte Cells |
| Q42263341 | Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea. |
| Q35998475 | Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers |
| Q50163355 | Functions of the Gallbladder |
| Q91634993 | Gall bladder: The metabolic orchestrator |
| Q26829300 | Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk |
| Q34627935 | Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis |
| Q37529052 | Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis |
| Q97643831 | Metabolic Messengers: fibroblast growth factor 15/19 |
| Q64085995 | Molecular Pathogenesis of Cholangiocarcinoma |
| Q57098775 | Neurotensin contributes to pediatric intestinal failure-associated liver disease via regulating intestinal bile acids uptake |
| Q56020294 | Newly Identified Mechanisms of Total Parenteral Nutrition Related Liver Injury |
| Q36786270 | Nuclear receptors as drug targets in cholestatic liver diseases |
| Q38074995 | Nuclear receptors in bile acid metabolism |
| Q24628720 | Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids |
| Q37584099 | Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge |
| Q26748537 | Recent advances in understanding and managing cholestasis |
| Q57821646 | Recent advances in understanding and managing cholesterol gallstones |
| Q43614017 | Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population |
| Q36417890 | Renal Production, Uptake, and Handling of Circulating αKlotho |
| Q90656773 | Rifampicin, not vitamin E, suppresses parenteral nutrition-associated liver disease development through the pregnane X receptor pathway in piglets |
| Q38781182 | Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis |
| Q34460281 | Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch |
| Q57113921 | Solute Carrier Organic Anion Transporter Family Member 3A1 is a Bile Acid Efflux Transporter in Cholestasis |
| Q38176101 | Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations |
| Q37556251 | The portal-drained viscera release fibroblast growth factor 19 in humans |
| Q47114074 | The relation between gallstone disease and cardiovascular disease |
| Q34418685 | Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals |
| Q37575666 | c-Fos mediates repression of the apical sodium-dependent bile acid transporter by fibroblast growth factor-19 in mice |
Search more.